Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1

Cancer Science

Volumn 99, Issue 10, 2008, Pages 1950-1959

  Shiota, Masaki ^a,b   Izumi, Hiroto ^a   Miyamoto, Naoya ^a   Onitsuka, Takamitsu ^a   Kashiwagi, Eiji ^a,b   Kidani, Akihiko ^a   Hirano, General ^a   Takahashi, Mayu ^a   Ono, Mayumi ^c   Kuwano, Michihiko ^d   Naito, Seiji ^b   Sasaguri, Yasuyuki ^d   Kohno, Kimitoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; HIGH MOBILITY GROUP B1 PROTEIN; HYDROGEN PEROXIDE; PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 2; PEROXIREDOXIN 3; PEROXIREDOXIN 4; PEROXIREDOXIN 5; TRANSCRIPTION FACTOR ETS; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL PROTECTION; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HYPOXIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SENSITIZATION; SQUAMOUS CELL CARCINOMA;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HUMANS; KB CELLS; MALE; PEROXIREDOXINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-ETS;

EID: 54949152283     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00912.x     Document Type: Article

References (41)

1. Finkel T. Oxygen radicals and signaling. Curr Opin Cell Biol 1998; 10: 248-53.
2. Neumann CA, Krause DS, Carman CV et al. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 2003; 424: 561-5.
3. Chang JW, Jeon HB, Lee JH et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 2001; 289: 507-12.
4. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003; 9: 3418-24.
5. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 2006; 175: 1512-16.
6. Chen MF, Keng PC, Shau H et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 2006; 64: 581-91.
7. Ohga T, Koike K, Ono M et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56: 4224-8.
8. Imamura T, Izumi H, Nagatani G et al. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem 2001; 276: 7534-40.
9. Araki M, Nanri H, Ejima K et al. Antioxidant function of the mitochondrial protein SP-22 in the cardiovascular system. J Biol Chem 1999; 274: 2271-8.
10. Ise T, Nagatani G, Imamura T et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999; 59: 342-6.
11. Uramoto H, Izumi H, Ise T et al. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 2002; 277: 31694-702.
12. Igarashi T, Izumi H, Uchiumi T et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007; 26: 4749-60.
13. Wakasugi T, Izumi H, Uchiumi T et al. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007; 26: 5194-203.
14. Ryuto M, Ono M, Izumi H et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996; 271: 28220-8.
15. Shiota M, Izumi H, Onitsuka T et al. Twist and p53 reciprocally regulate target genes via direct interaction. Oncogene Epub ahead of print. [Cited 26 May 2008.]
16. Dittmer J, Pise-Masison CA, Clemens KE, Choi KS, Brady JN. Interaction of human T-cell lymphotropic virus type I Tax, Ets1, and Sp1 in transactivation of the PTHrP P2 promoter. J Biol Chem 1997; 272: 4953-8.
17. Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev 1998; 12: 462-72.
18. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
19. Yanagawa T, Ishikawa T, Ishii T et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 1999; 145: 127-32.
20. Wonsey DR, Zeller KI, Dang CV. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA 2002; 99: 6649-54.
21. Oikawa T. ETS transcription factors: Possible targets for cancer therapy. Cancer Sci 2004; 95: 626-33.
22. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005; 41: 2462-78.
23. Maroulakou IG, Bowe DB. Expression and function of Ets transcription factors in mammalian development: A regulatory network. Oncogene 2000; 19: 6432-42.
24. Bartel FO, Higuchi T, Spyropoulos DD. Mouse models in the study of the Ets family of transcription factors. Oncogene 2000; 19: 6443-54.
25. Sementchenko VI, Watson DK. Ets target genes: Past, present and future. Oncogene 2000; 19: 6533-48.
26. John S, Reeves RB, Lin JX et al. Regulation of cell-type-specific interleukin-2 receptor alpha-chain gene expression: Potential role of physical interactions between Elf-1, HMG-I (Y), and NF-kappa B family proteins. Mol Cell Biol 1995; 15: 1786-96.
27. Koizumi S, Fisher RJ, Fujiwara S et al. Isoforms of the human ets-1 protein: Generation by alternative splicing and differential phosphorylation. Oncogene 1990; 5: 675-81.
28. Fisher RJ, Fivash M, Casas-Finet J et al. Real-time DNA binding measurements of the ETS1 recombinant oncoproteins reveal significant kinetic differences between the p42 and p51 isoforms. Protein Sci 1994; 3: 257-66.
29. Sapi E, Flick MB, Rodov S, Kacinski BM. Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res 1998; 58: 1027-33.
30. Sementchenko VI, Schweinfest CW, Papas TS, Watson DK. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 1998; 17: 2883-8.
31. Nagatani G, Nomoto M, Takano H et al. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res 2001; 61: 1592-7.
32. Zhang C, Kavurma MM, Lai A, Khachigian LM. Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21 WAF1/ Cip1: ETS-1 regulates basal and inducible p21 WAF1/Cip1 transcription via distinct cis-acting elements in the p21 WAF/Cip1 promoter. J Biol Chem 2003; 278: 27903-9.
33. Myers E, Hill AD, Kelly G et al. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer. Clin Cancer Res 2005; 11: 2111-22.
34. Elvert G, Kappel A, Heidenreich R et al. Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 2003; 278: 7520-30.
35. Ito H, Duxbury M, Benoit E et al. Prostaglandin E2 enhances pancreatic cancer invasiveness through an Ets-1-dependent induction of matrix metalloproteinase-2. Cancer Res 2004; 64: 7439-46.
36. 2-induced cell death in MCF-7 cell lines. J Cell Biochem 2007; 101: 1038-45.
37. Berggren MI, Husbeck B, Samulitis B, Baker AF, Gallegos A, Powis G. Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. Arch Biochem Biophys 2001; 392: 103-9.
38. Yuan J, Murrell GA, Trickett A, Landtmeters M, Knoops B, Wang MX. Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss cellular function during oxidative stress. Biochem Biophys Acta 2004; 1693: 37-45.
39. Banmeyer I, Marchand C, Verhaeghe C, Vucic B, Rees JF, Knoops B. Overexpression of human peroxiredoxin 5 in subcellular compartments of Chinese hamster ovary cells: Effects on Cytotoxicity and DNA damage caused by peroxides. Free Radic Biol Med 2004; 36: 65-77.
40. Egler RA, Fernandes E, Rothermund K et al. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 2005; 24: 8038-50.
41. Kropotov AV, Grudinkin PS, Pleskach NM, Gavrilov BA, Tomilin NV, Zhivotovsky B. Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks. FEBS Lett 2004; 572: 75-9.